Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;10(18):6304-6309.
doi: 10.1002/cam4.4172. Epub 2021 Aug 12.

Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer

Cedric Pobel  1 , Edouard Auclin  1 , Diego Teyssonneau  2 , Brigitte Laguerre  3 , Mathilde Cancel  4 , Elouen Boughalem  5 , Johanna Noel  1 , Pierre Emmanuel Brachet  6 , Denis Maillet  7 , Philippe Barthelemy  8 , Carole Helissey  9 , Constance Thibault  1 , Stéphane Oudard  1
Affiliations

Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer

Cedric Pobel et al. Cancer Med. 2021 Sep.

Abstract

Introduction: Cabazitaxel multiple rechallenges may be a treatment option in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) who had a good initial response to cabazitaxel and who are still fit to receive it. Our objective was to assess the efficacy and toxicity of multiple rechallenges.

Patients and methods: We retrospectively identified 22 mCRPC patients previously treated with docetaxel and/or androgen receptor-targeted agents who received multiple cabazitaxel rechallenges in 9 French centers. Cabazitaxel was initiated at a dose of 25 mg/m2 q3week. A reduced dose (20 mg/m2 q3w) or an alternative schedule (mainly 16 mg/m2 q2w) was increasingly used for subsequent rechallenges. Progression-free survival, prostate-specific antigen (PSA) response, best clinical response, and grade ≥3 toxicities were collected. Overall survival was calculated from various time points.

Results: Twenty-two patients with an initial response to cabazitaxel were rechallenged at least twice. The median number of cabazitaxel cycles was 7 at first cabazitaxel treatment, 6 at first rechallenge, and 5 at subsequent rechallenges. Median progression-free survival at first rechallenge was 9.6 months and 5.6 months at second rechallenge. Median overall survival was 50.9 months from the first cabazitaxel dose, 114.9 months from first life-extending therapy initiation in mCRPC, and 105 months from mCRPC diagnosis. There was no cumulative grade ≥3 neuropathy or nail disorder and one case of febrile neutropenia.

Conclusion: Cabazitaxel multiple rechallenges may be a treatment option without cumulative toxicity in heavily pretreated patients having a good response to first cabazitaxel use and still fit to receive it.

Novelty & impact statements: Patients with metastatic castration-resistant prostate cancer can be treated with Cabazitaxel after docetaxel and androgen receptor-targeted agent. This chemotherapy can be used multiple times with efficacy and manageable toxicity.

Keywords: cancer management; chemotherapy; metastasis; prostate cancer; urological oncology.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

FIGURE 1
FIGURE 1
Swimmer plot summarizing treatment strategies from the diagnosis of mCRPC for each patient rechallenged with cabazitaxel. mCRPC: metastatic castration‐resistant prostate cancer
See this image and copyright information in PMC

References

    1. Nuhn P, De Bono JS, Fizazi K, et al. Update on systemic prostate cancer therapies: management of metastatic castration‐resistant prostate cancer in the era of precision oncology. Eur Urol. 2019;75:88‐99. - PubMed
    1. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration‐resistant prostate cancer. N Engl J Med. 2020;382(22):2091‐2102. - PubMed
    1. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration‐resistant prostate cancer progressing after docetaxel treatment: a randomised open‐label trial. Lancet. 2010;376:1147‐1154. - PubMed
    1. Oudard S, Fizazi K, Sengeløv L, et al. Cabazitaxel versus docetaxel as first‐line therapy for patients with metastatic castration‐resistant prostate cancer: a randomized phase III trial‐FIRSTANA. J Clin Oncol. 2017;35:3189‐3197. - PubMed
    1. Khalaf DJ, Annala M, Taavitsainen S, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration‐resistant prostate cancer: a multicentre, randomised, open‐label, phase 2, crossover trial. Lancet Oncol. 2019;20:1730‐1739. - PubMed

MeSH terms